Sangamo Therapeutics, Inc. (SGMO) Position Trimmed by Granahan Investment Management Inc. MA
Granahan Investment Management Inc. MA lessened its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 34.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 465,090 shares of the biopharmaceutical company’s stock after selling 241,769 shares during the period. Granahan Investment Management Inc. MA owned approximately 0.55% of Sangamo Therapeutics worth $6,976,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Blair William & Co. IL grew its holdings in Sangamo Therapeutics by 4.3% during the second quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 500 shares during the period. Aperio Group LLC purchased a new stake in Sangamo Therapeutics during the second quarter worth $108,000. Principal Financial Group Inc. boosted its position in Sangamo Therapeutics by 6.8% during the second quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 832 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Sangamo Therapeutics during the third quarter worth $118,000. Finally, Virtu KCG Holdings LLC purchased a new stake in Sangamo Therapeutics during the second quarter worth $124,000. 64.35% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Sangamo Therapeutics, Inc. (SGMO) opened at $15.85 on Tuesday. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.02. Sangamo Therapeutics, Inc. has a 12-month low of $2.85 and a 12-month high of $18.40.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The business had revenue of $11.81 million for the quarter, compared to the consensus estimate of $10.37 million. During the same period in the prior year, the business earned ($0.27) earnings per share. The business’s revenue was up 333.0% on a year-over-year basis. research analysts predict that Sangamo Therapeutics, Inc. will post -0.73 EPS for the current year.
In other news, VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $15.25, for a total value of $228,750.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Saira Ramasastry sold 5,000 shares of the company’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $14.67, for a total value of $73,350.00. Following the completion of the sale, the director now owns 5,000 shares in the company, valued at $73,350. The disclosure for this sale can be found here. Insiders sold 84,433 shares of company stock worth $1,309,466 over the last 90 days. Company insiders own 5.50% of the company’s stock.
A number of research firms have commented on SGMO. Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Friday, August 18th. Jefferies Group reiterated a “buy” rating and set a $18.00 target price on shares of Sangamo Therapeutics in a research report on Friday, October 13th. Wedbush reiterated a “hold” rating and set a $6.00 target price on shares of Sangamo Therapeutics in a research report on Wednesday, November 15th. Piper Jaffray Companies upgraded Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 target price on the stock in a research report on Wednesday, November 15th. Finally, Barclays began coverage on Sangamo Therapeutics in a research report on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 target price on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Sangamo Therapeutics presently has a consensus rating of “Buy” and an average target price of $17.83.
Sangamo Therapeutics Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.